Predictive Biomarker for Endoscopic Therapy in Chronic Pancreatitis

Inclusion Criteria: * adults older than 18 years; * Cambridge III or IV criteria for Chronic Pancreatitis (CP); or M-ANNHEIM criteria for definitive chronic pancreatitis; * scheduled for endoscopic therapy for ductal obstruction (may include lithotripsy, pancreatic duct dilation, or stone extraction to facilitate successful stenting) as part of routine clinical care based on multidisciplinary review; * pain present for ≥ 3 days per week for ≥ 3 months; * average pain over the last week ≥ 4 on a 11-point numeric rating scale (NRS). Exclusion Criteria: * chronic pain syndrome other than CP; * episode of acute pancreatitis within 2 months of enrollment; * endoscopic therapy including Endoscopic retrograde cholangiopancreatography (ERCP), Endoscopic ultrasound (EUS) Guided Celiac Plexus Block or pancreatic surgery \< 6 months prior to enrollment; * active illicit drug use (excludes marijuana use); * American Society of Anesthesiologists classification \> 3; * immune-mediated pancreatitis or associated pancreatic neoplasms * Major neurological disease such as stroke, uncontrolled epilepsy, dementia * Diagnosis of schizophrenia * Chronic benzodiazepine use. Use of short acting benzodiazepine on as needed basis is acceptable if participant is able to hold benzodiazepine prior to EEG recording. * Pregnancy